fluorodeoxyglucose f18 has been researched along with epirubicin in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 13 (72.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Avril, N; Dose, J; Graeff, H; Jänicke, F; Kuhn, W; Nährig, J; Römer, W; Sattler, D; Schelling, M; Schwaiger, M; Werner, M | 1 |
| Burcombe, RJ; Emmott, J; Lowe, J; Makris, A; Pittam, M; Wong, WL | 1 |
| Conte, PF; Dani, D; Donati, S; Gennari, A; Giorgetti, A; Landucci, E; Mariani, G; Pisani, P; Poli, M; Puccini, G; Salvadori, B; Salvadori, PA; Sorace, O | 1 |
| Avril, N; Bader, M; Dose Schwarz, J; Hemminger, G; Jänicke, F; Jenicke, L | 1 |
| Park, KG; Smith, TA; Suttie, SA | 1 |
| Avril, N; Avril-Sassen, S; Dose-Schwarz, J; Jänicke, F; Lebeau, A; Mahner, S; Schwaiger, M; Tiling, R; Untch, M; Weber, C | 1 |
| Hama, Y; Nakagawa, K | 1 |
| Gallamini, A; Grimaldi, F; Nicolai, E; Pane, F; Picardi, M; Soricelli, A | 1 |
| Abel, U; Debus, J; Haag, GM; Haberkorn, U; Jäger, D; Lordick, F; Lorenzen, S; Münter, MW; Stange, A; von Gall, C; Weichert, W; Weitz, J | 1 |
| Helin, H; Karhumäki, L; Kauppi, JT; Kemppainen, J; Oksala, N; Räsänen, JV; Salo, JA; Sihvo, EI | 1 |
| Coussy, F; Cuvier, C; de Roquancourt, A; Espié, M; Giacchetti, S; Groheux, D; Hatt, M; Hindié, E; Marty, M; Vercellino, L | 1 |
| Berger, F; de Cremoux, P; de Roquancourt, A; Espié, M; Giacchetti, S; Groheux, D; Hamy, AS; Hatt, M; Hindié, E; Marty, M; Merlet, P | 1 |
| Hasebe, T; Hirokawa, E; Kuji, I; Matsuura, K; Osaki, A; Saeki, T; Shigekawa, T; Shimada, H; Sugitani, I; Sugiyama, M; Takahashi, T; Takeuchi, H; Ueda, S; Yamane, T | 1 |
| Alberini, JL; Bertrand, F; Champion, L; Fourme, E; Gontier, E; Lerebours, F; Wartski, M | 1 |
| Biard, L; Cuvier, C; de Cremoux, P; de Roquancourt, A; Espié, M; Giacchetti, S; Groheux, D; Hindié, E; Merlet, P; Resche-Rigon, M; Teixeira, L; Vercellino, L | 1 |
| Cheon, GJ; Chung, JK; Kang, KW; Kim, EE; Kim, YI; Lee, DS; Moon, WK; Paeng, JC; Yoon, HJ | 1 |
| Bassa, P; Capdevila, L; Garcia, JR; Pérez, C; Ramos, F; Valenti, V | 1 |
| Ålgars, A; Kemppainen, J; Ristamäki, R; Salminen, P; Sundström, J; Vihervaara, H | 1 |
4 trial(s) available for fluorodeoxyglucose f18 and epirubicin
| Article | Year |
|---|---|
Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Risk Assessment; Risk Factors; Sensitivity and Specificity; Treatment Outcome | 2005 |
Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Fluorouracil; Humans; Magnetic Resonance Imaging; Mammography; Mastectomy; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Ultrasonography, Mammary | 2010 |
Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Middle Aged; Nanoparticles; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Radiopharmaceuticals; Taxoids; Treatment Outcome | 2015 |
18F-FDG PET/CT to Predict Response to Neoadjuvant Chemotherapy and Prognosis in Inflammatory Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Epirubicin; Fluorodeoxyglucose F18; Fluorouracil; Humans; Image Interpretation, Computer-Assisted; Multimodal Imaging; Neoadjuvant Therapy; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
14 other study(ies) available for fluorodeoxyglucose f18 and epirubicin
| Article | Year |
|---|---|
Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Paclitaxel; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; ROC Curve; Sensitivity and Specificity; Tomography, Emission-Computed | 2000 |
Evaluation of good clinical response to neoadjuvant chemotherapy in primary breast cancer using [18F]-fluorodeoxyglucose positron emission tomography.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma in Situ; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Radiopharmaceuticals; Tomography, Emission-Computed; Treatment Outcome | 2002 |
Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Monitoring; Epirubicin; Female; Fluorodeoxyglucose F18; Gemcitabine; Glucose; Humans; Liver Neoplasms; Lung Neoplasms; Paclitaxel; Predictive Value of Tests; Radiopharmaceuticals; Remission Induction; Soft Tissue Neoplasms; Survival Analysis; Time Factors; Tomography, Emission-Computed; Treatment Outcome | 2000 |
[18F]2-fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil.
Topics: Adenocarcinoma; Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Epirubicin; Flow Cytometry; Fluorodeoxyglucose F18; Fluorouracil; Humans; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Stomach Neoplasms; Tumor Cells, Cultured | 2007 |
Early distant relapse in early stage triple-negative breast cancer: usefulness of FDG-PET for diagnosis of distant metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy Dosage; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2013 |
Fused FDG-PET/contrast-enhanced CT detects occult subdiaphragmatic involvement of Hodgkin's lymphoma thereby identifying patients requiring six cycles of anthracycline-containing chemotherapy and consolidation radiation of spleen.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Contrast Media; Cyclophosphamide; Disease-Free Survival; Epirubicin; Etoposide; Female; Fluorodeoxyglucose F18; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Liver; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prednisone; Prospective Studies; Radiopharmaceuticals; Recurrence; Spleen; Tomography, X-Ray Computed; Young Adult | 2011 |
Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.
Topics: Adenocarcinoma; Antineoplastic Agents; Capecitabine; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Fluorouracil; Germany; Humans; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Salvage Therapy; Taxoids; Treatment Outcome | 2011 |
Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Survival Rate; Taxoids; Tomography, X-Ray Computed | 2012 |
HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Positron-Emission Tomography; Radiopharmaceuticals; Receptor, ErbB-2; Survival Rate; Taxoids; Trastuzumab; Treatment Outcome | 2013 |
Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Taxoids; Tomography, X-Ray Computed; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
¹⁸F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Recurrence, Local; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Treatment Outcome; Triple Negative Breast Neoplasms | 2016 |
Prognostic Value of 68Ga-NOTA-RGD PET/CT for Predicting Disease-Free Survival for Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy and Surgery: A Comparison Study With Dynamic Contrast Enhanced MRI.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Contrast Media; Coordination Complexes; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Kaplan-Meier Estimate; Lymph Node Excision; Magnetic Resonance Imaging; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Oligopeptides; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Prognosis; Proportional Hazards Models; Prospective Studies; Radiopharmaceuticals; Taxoids | 2016 |
18F-FDG PET/CT in the Staging and Management of Breast Cancer: Value in Disease Outcome and Planning Therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Axilla; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Diphosphonates; Docetaxel; Epirubicin; Female; Fluorodeoxyglucose F18; Fluorouracil; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Letrozole; Lymph Node Excision; Lymph Nodes; Mastectomy; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Radiotherapy; Ribs; Taxoids; Triazoles; Zoledronic Acid | 2017 |
Perioperative EOX treatment in operable locally advanced gastroesophageal adenocarcinoma: Prediction of tumor response by FDG -PET and histopathology.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Oxaliplatin; Perioperative Care; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Stomach Neoplasms; Survival Rate; Young Adult | 2019 |